>>Signaling Pathways>> Apoptosis>>ICCB280

ICCB280

Catalog No.GC61414

ICCB280은 C/EBPα의 강력한 유도제입니다. ICCB280은 C/EBPα의 활성화와 다운스트림 표적(C/EBPε, G-CSFR 및 c-Myc)에 영향을 미쳐 말단 분화, 증식 정지 및 세포자멸사를 포함한 항백혈병 특성을 나타냅니다.

Products are for research use only. Not for human use. We do not sell to patients.

ICCB280 Chemical Structure

Cas No.: 2041072-41-5

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$216.00
재고 있음
5 mg
US$198.00
재고 있음
10 mg
US$351.00
재고 있음
25 mg
US$567.00
재고 있음
50 mg
US$1,080.00
재고 있음
100 mg
US$1,530.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ICCB280 is a potent inducer of C/EBPα. ICCB280 exhibits anti-leukemic properties including terminal differentiation, proliferation arrest, and apoptosis through activation of C/EBPα and affecting its downstream targets (such as C/EBPε, G-CSFR and c-Myc)[1][2].

ICCB280 (0.1-50 μM; 48 h) suppresses the HL-60 cell growth, with an IC50 of 8.6 μM[1].ICCB280 (10 μM; 2-8 d) increases the C/EBPα expression (mRNA and protein) and modulates its target genes in HL-60 cells[1].ICCB280 (10 μM; 7 d) induces granulocytic differentiation and subsequent apoptosis in HL-60 cells[1]. Cell Viability Assay[1] Cell Line: HL-60 cells

[1]. Radomska HS, et, al. A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation. J Biomol Screen. 2015 Oct;20(9):1150-9. [2]. Sridhar R, et, al. Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPα. Molecules. 2018 Aug 3;23(8):1938.

리뷰

Review for ICCB280

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ICCB280

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.